Urban Health Today Editors

Urban Health Today

Enrollment of ethnic minorities into academic clinical trials of multiple myeloma (MM) in the United Kingdom was below expected rates, according to a <a href="https://ash.confex.com/ash/2021/webprogram/Paper149148.html">poster</a> presentation at the 2021 American Society of Hematology (ASH) Annual Meeting.According to Rakesh Popat, University College London Hospitals NHS foundation Trust, London, UK, who presented the data, the incidence of MM varies by ethnicity with Black patients about twice as likely to develop MM compared to White or Asian patients. Ethnic minorities have been reported to be underrepresented in clinic trials, but it is unknown if these disparities exist in a state-funded health care system where access to health care is free and should be equitable.Popat and colleagues collected information on ethnicity, baseline demographics, progression-free survival, and overall survival from patients enrolled into first-line UK academic transplant eligible and transplant ineligible trials (Myeloma IX, XI, and XIV trials) and at first relapse (Myeloma X and XII trials). These trials enrolled patients from 2003 to 2021. Patients were enrolled across 120 centers covering a wide geographical distribution in the UK.According to Popat, data from the National Cancer Registration and Analysis Service (NCRAS) showed an expected distribution of cases at 85.5% of cases White, 5.4% of cases Black, and 3.6% of cases to be Asian.In all, 7291 patients were enrolled in these trials over 18 years. The ethnic distribution was 93.8% White, 2.2% Black, 1.8% Asian, and 0.6% other. The researchers noted that the skew of White patient enrollment was more apparent in transplant ineligible trials.Enrollment distribution by ethnicity was consistent over the 18 years with no change in diversity over time despite there being an increase in non-White populations.The researchers found that all ethnic groups derived and overall survival benefit from novel agents within trials that were not otherwise routinely available. However, a substantial proportion of ethnic minorities were not enrolled, particularly in transplant ineligible trials. This limited their potential survival gains.Popat said that understanding the causes of inequality and addressing these is a priority for the UK-MRA to ensure that all groups can potentially benefit, and that trial results are representative of the UK population.

Rebecca Araujo

AI-Driven Insulin Support: Are These Tools Ready for Diabetes Care?

Diabetes

Lou Portero

Heart Rate Complexity May Predict Cognitive Decline in Older Adults

Alzheimer's & Dementia

Female Cancer Survivors Face Higher Rates of Fatigue and Depression, Study Finds

Women's Neurology

Latest News

Ethnic Minorities Under-Enrolled in UK Myeloma Trials

Multiple Myeloma

Enrollment of ethnic minorities into academic clinical trials of multiple myeloma (MM) in the United Kingdom was below ...

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe